#USA #New York #Class Action #Gross Law Firm #BioAge Labs

Significant Class Action Lawsuit for BioAge Investors

The Gross Law Firm has taken the initiative to inform investors of BioAge Labs, Inc. (NASDAQ: BIOA) regarding a pending class action lawsuit. This announcement serves as a crucial reminder for all shareholders who purchased shares during the designated class period, specifically in connection with BioAge's registration statement for its initial public offering that took place around September 26, 2024.

Background of the Class Action

The class action is intended for all shareholders who acquired BIOA shares according to the IPO registration. Allegations in the suit center on a significant issue that has arisen quite recently. On December 6, 2024, BioAge manifested a shocking decision to cease the STRIDES Phase 2 trial of its lead product candidate, azelaprag. The announcement cited concerning safety issues regarding elevated liver transaminase levels in trial participants, which alarmed many investors. Prior to this, BioAge had emphasized azelaprag's immense potential during its IPO, particularly for patients undergoing obesity therapy with incretin drugs, creating a sense of optimism in the investor community. Following the alarming news, the stock experienced a drastic decline, plummeting from $20.09 per share to just $4.65 in a single day.

Key Information for Shareholders

The deadline for shareholders to register for this class action is March 10, 2025. It’s crucial to act promptly to ensure your eligibility for potential recovery. The Gross Law Firm encourages all affected shareholders to reach out and express their interest in being involved, although becoming a lead plaintiff is not a requisite for participating in the recovery process. Once registered, shareholders will gain access to portfolio monitoring software to provide them with updates throughout the legal proceedings.

An important aspect to note is that participating in the class action involves no cost or obligation for the investors. Moreover, the Gross Law Firm aims to aid investors affected by misleading statements or omissions made by BioAge that resulted in inflated stock prices.

Why Choose the Gross Law Firm?

Recognized nationally, the Gross Law Firm focuses on protecting investors’ rights against deceitful practices in the corporate world. They strive to hold companies accountable for irresponsible activities that put the interests of shareholders at risk. The firm’s commitment to responsible corporate conduct underlines their dedication to ensuring investors receive fair treatment.

Potential plaintiffs are strongly advised to pay attention to this lawsuit, culminating on March 10, 2025. As they prepare for the next steps, shareholders are encouraged to connect with the firm to navigate through this turbulent situation effectively.

For more details regarding your rights or to begin the registration process, you can visit the Gross Law Firm's website or reach their offices directly at the contact information provided below.

Contact Details:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

In conclusion, the Gross Law Firm stands ready to assist BioAge investors as they navigate the complexities of this pending legal action. Shareholders are urged to act swiftly and make their voices heard in matters affecting their investments.